Companies in #Gout

Crystalys Therapeutics is a clinical-stage biotechnology company developing dotinurad, a Phase 3-ready URAT1 inhibitor for the treatment of gout. The company's lead asset is positioned to rival Sobi's gout franchise.

Curanex Pharmaceuticals is a developmental-stage pharmaceutical company discovering, developing, and commercializing botanical drugs for inflammatory and other serious diseases. Its lead candidate, Phyto-N, is being advanced across ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout, with a 2026 pipeline expansion into cancer cachexia and advanced cancer supportive care. The company completed GMP manufacturing and toxicology milestones supporting a planned Q4 2026 IND submission for ulcerative colitis. Curanex (formerly Fordman Pharma, renamed November 2023) listed on Nasdaq in August 2025 at $4.00 per share and implemented a 1-for-20 reverse stock split effective August 20, 2026 to maintain listing compliance, reducing shares outstanding to approximately 1.57 million.

Clinical-stage biotech developing oral NLRP3 inflammasome inhibitors, led by dapansutrile (OLT1177), which has advanced from discovery into later-stage clinical development across inflammatory and age-related diseases.